Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.

Cancer science - 1 Apr 2016

Mizuuchi Hiroshi, Suda Kenichi, Murakami Isao, Sakai Kazuko, Sato Katsuaki, Kobayashi Yoshihisa, Shimoji Masaki, Chiba Masato, Sesumi Yuichi, Tomizawa Kenji, Takemoto Toshiki, Sekido Yoshitaka, Nishio Kazuto, Mitsudomi Tetsuya

Abstract excerpt

Mutant selective epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as rociletinib and AZD9291, are effective for tumors with T790M secondary mutation that become refractory to first-generation EGFR-TKI. However, acquired resistance to these prospective drugs is anticipated considering the high adaptability of cancer cells and the mechanisms remain largely obscure. Here, CNX-2006 (tool...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Oncogenes

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Pyrimidines

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 26845230
DOI: 10.1111/cas.12905
PMCID: PMC4832847

Genes

MET
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.PMID 26845230Read ↗

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Semantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read ↗

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.Semantic proximity Read ↗

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Semantic proximity Read ↗

Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.Semantic proximity Read ↗

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Semantic proximity Read ↗

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment StrategySemantic proximity Read ↗

Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.Semantic proximity Read ↗

Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.Semantic proximity Read ↗

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.